Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 321

Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit

Posted by fidest press agency su giovedì, 12 aprile 2018

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit. The presentation will take place on April 27th, 2018 from 8:15am – 8:30am local time, in Honolulu, Hawaii. The OpRegen® data will be presented by one of our principal investigators, Dr. Eyal Banin, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
The summit takes place just prior to the 2018 annual meeting of the Association for Research in Vision and Ophthalmology, where BioTime is expected to present in two separate sessions. The Retinal Cell and Gene Therapy Innovation Summit is becoming one of the world’s most comprehensive overviews of the promising research underway for emerging gene, cell, and novel therapies targeting multiple degenerative and inherited retinal diseases. The summit will advance collaborative efforts among physicians, industry, and scientists to address the large unmet needs associated with these diseases.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: